Breast Cancer | Unmet Need | Metastatic Triple-Negative Breast Cancer | US/EU | 2022
Triple-negative breast cancer is an aggressive disease with high unmet need. There has been a historical lack of targeted therapies, although the treatment landscape has evolved with the approval of the PARP inhibitors Lynparza (AstraZeneca) and Talzenna (Pfizer) and the immune checkpoint inhibitors Tecentriq (Roche / Genentech) (EU only) and Keytruda (Merck & Co.). The approval of the TROP2-targeted antibody-drug conjugate Trodelvy (Immunomedics) has also expanded treatment options. Despite the availability of new therapies, significant clinical and commercial opportunity remains for the development of new therapies to improve patient outcomes. Our Unmet Need module analyzes the key drivers of prescribing and assesses how emerging therapies can capitalize on these opportunities.
QUESTIONS ANSWERED
- What are the most important factors that drive medical oncologists’ prescribing decisions for triple-negative breast cancer?
- How do key current therapies perform on key clinical attributes for this patient population?
- What are the prevailing areas of unmet need and hidden opportunities in this patient population?
- What trade-offs across different clinical attributes and price are acceptable to surveyed medical oncologists for a new therapy for triple-negative breast cancer?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 63 U.S. and 30 European medical oncologists fielded in May 2022.
Key companies: Eisai, Roche / Genentech, Pfizer, AstraZeneca, Merck & Co., Gilead Sciences, Daiichi Sankyo.
Key drugs: Abraxane, Avastin, Halaven, Keytruda, Lynparza, Talzenna, Tecentriq, Trodelvy.
